GlassScriptPhysician profile
James T Beaton
NPI 1952416653
$2,014.99
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $124 · 2021: $503 · 2022: $612 · 2023: $534 · 2024: $82.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $616.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $420.11 | 2019-2024 | |
| Glaxosmithkline, LLC. | $386.30 | 2021-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $351.79 | 2019-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $307.99 | 2021-2023 | Ubrelvy, Vraylar |
| Amgen INC. | $90.77 | 2020-2024 | Prolia, Evenity, Repatha |
| Astrazeneca Pharmaceuticals LP | $69.70 | 2021-2023 | Farxiga |
| Abbott Laboratories | $69.53 | 2022-2023 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $55.21 | 2021 | |
| Sunovion Pharmaceuticals INC. | $49.30 | 2020-2022 | |
| Almatica Pharma LLC | $30.54 | 2022-2024 | Loreev Xr |
| Merck Sharp & Dohme LLC | $28.96 | 2021 | |
| Sumitomo Pharma America, INC. | $21.92 | 2023 | Gemtesa |
| Ge Healthcare | $20.50 | 2020 | |
| Mylan Specialty L.P. | $16.09 | 2019 | |
| Agios Pharmaceuticals, INC. | $15.93 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $15.61 | 2020 | |
| Xeris Pharmaceuticals, INC. | $14.67 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.18 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.79 | 2023 | Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.07 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Beaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.